172 results about "Infection disease" patented technology

The invention relates to an orthopedic postoperative drainage liquid infection risk identification method. Drainage liquid is regarded as system output jointly driven by postoperative local immune regulation and wound recovery; capturing a nonlinear time sequence curve; first-order derived trend modeling is carried out; abrupt change after the change rate is stable is analyzed; establishing a postoperative recovery normal path framework, and forming a standard recovery trend library by using drainage fluid dynamic parameters of non-infected cases; comparing the Euclidean offset degree and directional change between the drainage parameter behavior vector of the current patient and the standard trajectory; the change is converted into a visual recovery offset map, and infection prediction data is measured from a multi-day trend angle; constructing and identifying local abnormal signal aggregation; forming a framework of infection event transition to obtain clinical infection nodes of qualitative change caused by quantitative change; according to the method, early-stage accurate recognition can be realized, the intervention opportunity can be obviously advanced, single threshold misjudgment is avoided, the recognition accuracy and specificity are improved, the model adaptability is improved, and the recognition interpretability is enhanced.

Systems and methods for selecting a treatment regimen for a particular patient are provided. The treatment regimen is selected using a first data store including a first plurality of patient records for a first plurality of patients, and a second data store including efficacy rates of a plurality of treatment regimens against a plurality of infections and infection-causing pathogens. The system, or a user of the system, identifies a first infection of the particular patient and a first treatment regimen to be prescribed to treat the first infection. A second plurality of patient records is generated by identifying, in the first plurality of patient records of the first data store, patient records associated with diagnosis or treatment of the first infection. The second plurality of patient records are appended with efficacy rates for the first infection from the second data store. Systems and methods of the present disclosure can use these appended records to generate a dynamic model configured to determine a likelihood estimation that the first treatment regimen is an appropriate treatment regimen to treat the first infection.

The invention discloses application of salidroside in preparation of a preparation for resisting virus infection of macrobrachium rosenbergii, and relates to the field of antiviral application. The salidroside is injected into the macrobrachium rosenbergii infected with the DIV1 virus, so that the accumulative survival rate of the macrobrachium rosenbergii infected with the DIV1 virus can be remarkably increased, the replication capacity of the DIV1 virus is inhibited, and the relative expression quantity of antiviral genes is increased; the salidroside can be used as a medicine or a feed additive for preventing or treating antiviral infection of macrobrachium rosenbergii.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

The invention provides a rabbit-source BCR sequence primer group based on high-throughput single cell V (D) J sequencing and application of the rabbit-source BCR sequence primer group. The primer group comprises a specific nested PCR (Polymerase Chain Reaction) primer pair (the sequence is as shown in SEQ ID NO.1-12) aiming at a rabbit BCR heavy chain (IgA / IgE / IgG / IgM) and a light chain (IgK / IgL). Through microfluid single-cell separation, nested PCR amplification and high-throughput sequencing, the naturally paired rabbit BCR full-length V (D) J sequence can be efficiently obtained. According to the rabbit-derived BCR sequence sequencing primer provided by the invention, B cell receptor library information of different tissue sources can be quickly and efficiently obtained. According to the method, paired antibody sequence information can be specifically obtained, B cell response diversity after rabbit immunization vaccine or pathogen infection can be better known, and important data support is provided for design, optimization, effect evaluation and the like of biological products.

The present application relates to the technical field of micro-grafting, and provides a Xinggongguo seedling micro-grafting device and method, wherein the Xinggongguo seedling micro-grafting device comprises a fixing frame, a supporting plate, a displacement assembly, a top shell, a clamping assembly and a cutting assembly; the supporting plate is fixedly installed on the fixing frame; the displacement assembly is installed inside the fixing frame and is used for adjusting the position of the seedling to be grafted; the top shell is rotatably installed on the top of the fixing frame; the clamping assembly is installed on the supporting plate and the displacement assembly and is used for fixing the positions of the seedling to be grafted and the stock; and the cutting assembly is installed on the supporting plate and is used for cutting grooves in the clamped seedling to be grafted and the stock. Through the above technical scheme, the problem of low grafting success rate caused by the high possibility of infection of pathogenic bacteria due to the phenomenon that the grooves are not flush when cutting the small stock and scion in the prior art is solved.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Disclosed herein are compositions and methods useful for the prevention, treatment, reduction, or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol, including solid states thereof. Also presented herein is the surprising discovery that exposing a subject to the compound and / or compositions disclosed herein can prevent, treat, reduce, or ameliorate a condition related to a subject previously infected with a virus.

A protective apparatus for use in medical and dental procedures to prevent exposure and exchange of harmful substances between an area isolated by the apparatus and the environment of use. The apparatus includes a physical shield, a vacuum barrier, and an adjustable support frame. The apparatus further includes a vacuum connector for connecting the apparatus to a vacuum source, a vacuum conduit for flow communicating with the air around the perimeter of the physical shield such that the vacuum source draws air along with solid and liquid matter entrained in the air into the vacuum conduit, and a plurality of vacuum apertures located along the vacuum conduit for communicating the vacuum source with the air. The apparatus provides protection for persons in proximity to a source of harmful substances such as aerosols derived from patients infected with viruses or the like and more in particular corona viruses.

The invention provides a respiratory tract infection pathogen antibody spectrum detection method and a respiratory tract infection pathogen antibody spectrum detection system, and relates to the technical field of biomass energy industries. If yes, performing gain dynamic adjustment based on the instrument stability dynamic evaluation result and the data quality parameters, performing antibody spectrum detection by using the instrument subjected to gain dynamic adjustment, and if the instrument stability dynamic evaluation result is a normal instrument, directly performing antibody spectrum detection by using the instrument; performing flow velocity rationality dynamic evaluation based on the flux efficiency demand and the sample core parameter, and executing liquid flow dynamic adjustment based on the liquid flow quality control parameter according to a flow velocity rationality dynamic evaluation result; and dynamically generating the antibody spectrum of the respiratory tract infection pathogen based on the microsphere coding information and the fluorescence intensity signal output by the flow cytometry after the liquid flow dynamic regulation.

The invention belongs to the technical field of nano diagnosis and treatment agents, and particularly relates to a preparation method and application of a multi-field response type nano diagnosis and treatment agent, the preparation method of the multi-field response type nano diagnosis and treatment agent comprises a core layer, a middle shell layer and an outer wrapping layer, the core layer is DCNPs, the middle shell layer is Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs, and the outer wrapping layer is an Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs. And the outer coating layer is HA which is coated on the outer side of the Nd < 0.03 > Fe < 0.97 > Se < 2 >. According to the invention, a multi-mode therapy of membrane structure defect induction-oxidative stress-metabolism interference-energy blocking can be realized, the mucous barrier penetrating ability is good, the retention ability of DNH in a pulmonary infection focus is improved, efficient drug delivery is realized, real-time NIR-II diagnosis can be assisted, and the application prospect is wide. The efficient treatment of lung bacterial infection diseases is realized.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The invention relates to the field of bioengineering, in particular to a recombinant human herpes simplex virus as well as a construction method and application thereof. The recombinant human herpes simplex virus lacks US1, US2, US3, US4 and US5 virulence genes at the same time. The construction method comprises the following steps: constructing a donor plasmid, and constructing a cleavage plasmid; transfecting cells with the cleavage plasmids and the donor plasmids in proportion; and after the transfected cells are incubated, infecting with an HSV-1 virus, purifying, and verifying to obtain the recombinant virus. The donor plasmid constructed by the invention retains non-coding regions among US1, US2, US3, US4 and US5 genes, also retains initiation codons and termination codons of the US1, US2, US3, US4 and US5 genes, is added with a fluorescent tag sequence, and can knock out five virulence genes of HSV-1US1-US2-US3-US4-US5 at the same time. The neutralizing antibody titer result of the recombinant human herpes simplex virus is the same as that of a wild type, and a foundation is laid for vaccine preparation.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

To provide a device which improves accuracy of infection risk determination of an infection disease.SOLUTION: The infection risk estimation system comprises: means for acquiring positional information of a user; means for acquiring biological information of the user and information on an affecting disease; estimation means for estimating a disease infection risk (possibility of infection from a patient of an infection disease) of the user; and reporting means for reporting the disease infection risk of the user. The estimation means determines from the history of the positional information of a first user affected by a disease a second user who was in contact with the first user, estimates the active state of the first user in a period when the first user was in contact with the second user from the biological information of the first user, and estimates the infection risk of the second user from the active state of the first user and the feature of the disease. When it is estimated that the risk of the second user having infected by the disease is high, the reporting means gives a report on high possibility of the infection by the disease.SELECTED DRAWING: Figure 6

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The present invention discloses a method for constructing a dual-omics plasma fingerprint model and an infection diagnosis device of the dual-omics plasma fingerprint model constructed by using this method, which relates to the technical field of infection disease diagnosis. The construction method includes preprocessing plasma samples, preparing matrix materials, spotting samples and matrixes on a mass spectrometry target plate, collecting plasma metabolite fingerprints in nanoparticle-enhanced laser desorption ionization mass spectrometry, and collecting plasma protein fingerprints in organic matrix material-assisted laser desorption ionization mass spectrometry. The infection diagnosis device performs data analysis on the dual-omics plasma fingerprint map to obtain a diagnosis result, and has advantages such as high detection reproducibility, fast analysis speed, and less sample consumption, realizing high-efficiency diagnostic performance for different infection types.

A nanoliposome preparation, which is a liposome prepared with distearoylphosphatidylglycerol (DSPG), cholesterol and Biotin‑PEG3000‑cholesterol as a carrier, is surface-modified with ICAM‑1 monoclonal antibody, and is loaded with an AIE photosensitizer and Nicorandil. The nanoliposomes prepared by the present invention have targeted and responsive drug delivery to infected lesions, improve the enrichment of drugs at bacterial infection sites, and the components of the nanosystem can be cleaved by phospholipases in the infected microenvironment, which can achieve responsive release of drugs at bacterial infection sites and enhance the therapeutic effect. The present invention utilizes the hydrophobic shell and hydrophilic core of the liposome, and simultaneously loads hydrophobic NO donor molecules and hydrophilic AIE photosensitizers to achieve the synergistic treatment of bacterial infections with "photodynamic therapy" and "gas therapy", and has a better killing effect on drug-resistant bacteria.

The application provides a kind of detection system of infectious pathogen type based on 5 markers, the 5 markers include: GSDMD, p-MLKL, IL-6, PCT, CRP, the system includes the following modules: (1) detection model: the GSDMD of detection sample, p-MLKL, IL-6, PCT, CRP content;(2) analysis module: based on random forest algorithm, neural network algorithm is analyzed to data, constructs diagnosis bacterial infection model;(3) diagnosis module: based on machine learning algorithm model is judged to bacterial infection to be diagnosed sample.The system provided by the application reaches 0.909, the diagnostic accuracy rate, the sensitivity, specificity, positive predictive value and negative predictive value of diagnosis are as follows: 0.95, 0.85, 0.90, 0.92.

The invention provides an application of alkannin in treatment of nasopharyngeal carcinoma infected by EB (Epstein-Barr) virus. A large number of studies find that compared with nasopharyngeal carcinoma cells not infected with EB viruses, alkannin is more sensitive to the nasopharyngeal carcinoma cells infected with the EB viruses, and IC50 is lower. The shikonin can better inhibit the proliferation and migration ability of nasopharyngeal carcinoma cells infected by EB virus, and promote the apoptosis of the nasopharyngeal carcinoma cells. In addition, the in-vivo anti-tumor curative effect of the shikonin on the nasopharyngeal carcinoma cell xenotransplantation tumor model infected by the EB virus is obviously superior to that of the nasopharyngeal carcinoma cell xenotransplantation tumor model not infected by the EB virus. After treatment with alkannin, the tumor growth ability of the nasopharyngeal carcinoma cell xenotransplantation tumor model mouse infected by the EB virus is obviously weaker than that of the nasopharyngeal carcinoma cell xenotransplantation tumor model mouse not infected by the EB virus. In addition, alkannin has no obvious side effect when used for treating nasopharyngeal carcinoma caused by EB virus, and is high in safety.

The invention belongs to the technical field of microbiological detection, and particularly relates to a Klebsiella pneumoniae MLST typing primer group and method based on a hospital localized microbiological mNGS platform. The primer group comprises primer pairs for amplifying an rpoB gene, an infB gene, a pgi gene, a phoE gene, a gapA gene, an mdh gene and a tonB gene, and corresponding nucleotide sequences are as shown in SEQ ID NO: 1-14. According to the technical characteristics of short sequencing read length (50 bp) and single-ended sequencing of a next-generation sequencing platform in a hospital, the primer group for Klebsiella pneumoniae MLST housekeeping gene amplification is redesigned, and amplicons are adaptive to the sequencing working principle of the existing next-generation sequencing platform in the hospital by optimizing the length and position of the amplicons. By utilizing the primer group, the kit or the method, the genetic relationship between hospital infection pathogenic bacteria can be quickly and accurately judged (within 24 hours), the timeliness and scientificity of infection prevention and control are remarkably improved, and the primer group, the kit or the method have a wide clinical application prospect.

The present disclosure relates to the field of biology. In particular, the present disclosure relates to T cell activation-inducing marker assays useful, for example, in determining whether a subject was previously exposed to an antigen of interest, such as by infection with a pathogen; and kits and compositions related to the determination of the T cell activation inducing marker.

The invention belongs to the field of antibody drugs, and particularly relates to an antibody specifically bound with respiratory syncytial virus or an antigen binding fragment thereof and application. The invention discloses an antibody, nucleic acid for coding the antibody, an expression vector, engineering bacteria, engineering cells and application of the antibody in preparation of products for treating and detecting respiratory syncytial virus (RSV) infection diseases. The antibody disclosed by the invention has excellent binding capacity with the respiratory syncytial virus, and can be applied to prevention, diagnosis or treatment of related diseases caused by respiratory syncytial virus infection.

The invention belongs to the technical field of medicines, and particularly relates to application of IR808 in preparation of a medicine for treating eye bacterial infection diseases. According to the invention, IR808 is taken as a photosensitizer, laser irradiation is combined, and singlet oxygen generated by IR808 is utilized to play an antibacterial role. The developed eye drops, intraocular injections, sustained-release nanoparticles and gel preparations are designed aiming at the eye environment, and have good biocompatibility and stability. The treatment scheme in an animal model proves that pathogens including drug-resistant bacteria can be efficiently killed at low concentration, intraocular tissue damage caused by infection can be effectively relieved, and observable toxicity to intraocular cells and the whole body of an experimental animal is not shown. The invention provides a novel effective method for treating bacterial infection of eyes, especially for solving the drug resistance of antibiotics and improving the treatment safety.

The application belongs to the field of antibody drugs, and particularly relates to an antibody or antigen-binding fragment thereof specifically binding to respiratory syncytial virus and application thereof. The application discloses the antibody, nucleic acid encoding the antibody, expression vector, engineering bacteria and engineering cells, and application of the antibody in preparation of products for treating and detecting respiratory syncytial virus (RSV) infection diseases. The antibody in the application has excellent binding capacity to respiratory syncytial virus, and can be applied in prevention, diagnosis or treatment of diseases caused by respiratory syncytial virus infection.

The present application relates to a touch control elevator button with ultraviolet disinfection function and a disinfection method thereof, and belongs to the field of elevators, solving the problem of cross infection caused by bacteria or viruses easily adhered to the button by repeated contact of elevator passengers in the prior art. The present application comprises: a touch button capable of triggering the start of the elevator under the pressing of the passengers, a button window is opened on one side of the shell, and the passengers can contact the touch button through the button window; a rotating mechanism can drive the touch button to switch positions between the button window and the ultraviolet disinfection lamp, enabling sequential use of multiple touch buttons and achieving ultraviolet disinfection of the touch button. The present application realizes real-time disinfection of the elevator button, avoiding the risk of infection of the virus when the passengers take the elevator.

The invention relates to a kit for early differential diagnosis of EBV-HLH and a method for auxiliary diagnosis of EBV-HLH. The kit comprises an EBV nucleic acid detection reagent and a miRNA-375 detection reagent. The kit provided by the invention is used for combined detection of EBV-DNA and miRNA-375 in a detection sample, and when an EBV-DNA detection result is greater than 5000 copies / mL and a miRNA-375 detection CT value is less than 35, suspected EBV-HLH is diagnosed. The invention not only provides a specific diagnostic index for EB infected diseases, but also serves as a reliable auxiliary diagnostic tool for EBV-HLH and other EB virus infection related diseases. When the kit provided by the invention is used for identifying and diagnosing EBV-HLH, the sensitivity and the accuracy are higher.

The present invention belongs to the field of drug therapy, and specifically relates to the use of methyl parahydroxybenzoate and its sodium salt in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of methyl parahydroxybenzoate, its sodium salt and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of methyl parahydroxybenzoate and its sodium salt inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in treating pneumonia caused by HCoV-229E virus infection was conducted. The results showed that methyl parahydroxybenzoate and its sodium salt inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.